News

FDA advisory panel nixes approval of drug-device for liver metastases

Publish date: May 8, 2013

 

AT AN FDA ADVISORY PANEL MEETING

About 2,000 cases of ocular melanoma are diagnosed annually in the United States and about 50% metastasize, most often to the liver, according to Delcath. In Europe and Australia, the company markets the device for a broad range of liver metastases, not just those caused by ocular melanoma, according to the company.

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

Abiraterone reduced morbidity in mCRPC patients
MDedge Surgery
Third drug approved for metastatic, treatment-resistant GIST
MDedge Surgery
Lipid metabolism genes linked to breast cancer subtype
MDedge Surgery
Breast cancer: Cardiac risk increases with radiation dose to heart
MDedge Surgery
Contralateral prophylactic mastectomy adds complications
MDedge Surgery
New blood test could identify early pancreatic cancer
MDedge Surgery
Designer T cells take aim at liver metastases
MDedge Surgery
High CRP augurs worse outcomes from palliative surgery for cancer
MDedge Surgery
Mammography screening at 75 may have value
MDedge Surgery
FDA advisory panel decides tivozanib falls short for advanced renal cell carcinoma
MDedge Surgery

Related Articles